FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Prostate Cancer
Relevance: Medium-High
Strength of Science: Medium-High
Study : Teens and young adults respond well to learning about familial cancer risk
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer
Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.
This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors. (posted 9/6/2022)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Physical activity may decrease fatigue associated with cancer treatment
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: Cancer patients who are experiencing fatigue related to cancer or its treatment.
Many cancer survivors experience fatigue during and after they complete treatment. This study looked at the effect of home-based physical activity on fatigue in cancer survivors. It also looked at whether frequent counseling encouraged people to start and continue their exercise routines. (Posted 8/1/22). Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : The hidden financial burden of treating cancer care symptoms
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People who are experiencing side effects due to cancer treatment or cancer.
Drugs commonly used to treat symptoms of cancer and cancer treatment side effects can cost thousands of dollars out of pocket for patients, depending on what drugs are used. (Posted 6/29/2022). Este artículo está disponible en español.
Read More
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Study : Do artificial sweeteners increase the risk of cancer?
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People who consume artificial sweeteners
A large study of adults in France suggests that artificial sweeteners may increase the risk of certain cancers. (posted 6/21/2022). Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Metastatic prostate cancer cases increased as screening use declined
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People who are concerned about their own or their loved one’s risk of prostate cancer
The number of people diagnosed with metastatic prostate cancer increased following a change in recommendations around the use of routine prostate cancer screening. (posted 6/13/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Research Timeline: Post Approval
Update : New drug approved for metastatic prostate cancer
Most relevant for: People who have been diagnosed with metastatic prostate cancer.
The FDA approved a new treatment for metastatic castration-resistant prostate cancer. They also approved a test that can be used to identify patients who would benefit from this new treatment. (Posted 5/10/22)
Este artículo está disponible en español.
Read More
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Increasing melatonin use raises concerns
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: people who take or consider taking melatonin to help with sleep.
Adult use of melatonin as a sleep aid has increased even though its benefits and risks are not well understood. This study looked at trends in melatonin use over the last 19 years. (Posted 4/14/2022)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Cannabis use among breast cancer patients
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People interested in using cannabis to relieve treatment side effects.
This study looked at patterns of cannabis use among breast cancer patients who are members of online health communities. Almost half of the study participants reported using cannabis to help manage treatment symptoms and side effects. The study also looked at reasons why patients used cannabis, where they obtained it and whether they perceived cannabis to be safe. While this study only looked at cannabis use among breast cancer patients it is likely results would be similar among patients diagnosed with other types of cancers. (posted 1/25/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Bone-protecting drugs cut the risks for fractures caused by metastatic prostate cancer treatments
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with metastatic castration resistant prostate cancer
Skeletal problems, especially bone fractures, are common in patients with advanced prostate cancer. To prevent these, many guidelines recommend the use of bone-protecting agents during treatment. The importance of giving a bone-protecting agent when treating patients with metastatic castration-resistant prostate cancer and bone metastases was confirmed in early results of an ongoing phase III trial. (11/5/21)
Este artículo está disponible en español.
Read More
Search XRAY studies and Articles
This Portal Sponsored By:
